180 related articles for article (PubMed ID: 30761293)
1. Insight Into the Binding Mechanism of p53/pDIQ-MDMX/MDM2 With the Interaction Entropy Method.
Li M; Cong Y; Li Y; Zhong S; Wang R; Li H; Duan L
Front Chem; 2019; 7():33. PubMed ID: 30761293
[TBL] [Abstract][Full Text] [Related]
2. Molecular investigation of the dual inhibition mechanism for targeted P53 regulator MDM2/MDMX inhibitors.
Zhao X; Xiong D; Luo S; Duan L
Phys Chem Chem Phys; 2022 Jul; 24(27):16799-16815. PubMed ID: 35775962
[TBL] [Abstract][Full Text] [Related]
3. Structure-based design of high affinity peptides inhibiting the interaction of p53 with MDM2 and MDMX.
Phan J; Li Z; Kasprzak A; Li B; Sebti S; Guida W; Schönbrunn E; Chen J
J Biol Chem; 2010 Jan; 285(3):2174-83. PubMed ID: 19910468
[TBL] [Abstract][Full Text] [Related]
4. Probing Origin of Binding Difference of inhibitors to MDM2 and MDMX by Polarizable Molecular Dynamics Simulation and QM/MM-GBSA Calculation.
Chen J; Wang J; Zhang Q; Chen K; Zhu W
Sci Rep; 2015 Nov; 5():17421. PubMed ID: 26616018
[TBL] [Abstract][Full Text] [Related]
5. Computational studies of difference in binding modes of peptide and non-peptide inhibitors to MDM2/MDMX based on molecular dynamics simulations.
Chen J; Zhang D; Zhang Y; Li G
Int J Mol Sci; 2012; 13(2):2176-2195. PubMed ID: 22408446
[TBL] [Abstract][Full Text] [Related]
6. Calculation of hot spots for protein-protein interaction in p53/PMI-MDM2/MDMX complexes.
Huang D; Qi Y; Song J; Zhang JZH
J Comput Chem; 2019 Apr; 40(9):1045-1056. PubMed ID: 30549062
[TBL] [Abstract][Full Text] [Related]
7. Structure-based designing efficient peptides based on p53 binding site residues to disrupt p53-MDM2/X interaction.
Rasafar N; Barzegar A; Mehdizadeh Aghdam E
Sci Rep; 2020 Jul; 10(1):11449. PubMed ID: 32651397
[TBL] [Abstract][Full Text] [Related]
8. Revealing binding selectivity of ligands toward murine double minute 2 and murine double minute X based on molecular dynamics simulations and binding free energy calculations.
Shi S; Sui K; Liu W; Lei Y; Zhang S; Zhang Q
J Biomol Struct Dyn; 2020 Oct; 38(17):5081-5094. PubMed ID: 31755361
[TBL] [Abstract][Full Text] [Related]
9. Molecular modeling and molecular dynamics simulation studies on pyrrolopyrimidine-based α-helix mimetic as dual inhibitors of MDM2 and MDMX.
Lu SY; Jiang YJ; Zou JW; Wu TX
J Mol Graph Model; 2011 Sep; 30():167-78. PubMed ID: 21820342
[TBL] [Abstract][Full Text] [Related]
10. Systematic mutational analysis of peptide inhibition of the p53-MDM2/MDMX interactions.
Li C; Pazgier M; Li C; Yuan W; Liu M; Wei G; Lu WY; Lu W
J Mol Biol; 2010 Apr; 398(2):200-13. PubMed ID: 20226197
[TBL] [Abstract][Full Text] [Related]
11. Design of ultrahigh-affinity and dual-specificity peptide antagonists of MDM2 and MDMX for P53 activation and tumor suppression.
Li X; Gohain N; Chen S; Li Y; Zhao X; Li B; Tolbert WD; He W; Pazgier M; Hu H; Lu W
Acta Pharm Sin B; 2021 Sep; 11(9):2655-2669. PubMed ID: 34589387
[TBL] [Abstract][Full Text] [Related]
12. Molecular dynamics simulations studies and free energy analysis on inhibitors of MDM2-p53 interaction.
Niu RJ; Zheng QC; Zhang JL; Zhang HX
J Mol Graph Model; 2013 Nov; 46():132-9. PubMed ID: 24211465
[TBL] [Abstract][Full Text] [Related]
13. Medicinal Chemistry Strategies to Disrupt the p53-MDM2/MDMX Interaction.
Lemos A; Leão M; Soares J; Palmeira A; Pinto M; Saraiva L; Sousa ME
Med Res Rev; 2016 Sep; 36(5):789-844. PubMed ID: 27302609
[TBL] [Abstract][Full Text] [Related]
14. Functional Interrogation of the N-Terminal Lid of MDMX in p53 Binding via Native Chemical Ligation.
Chen X; Lu W
Chem Pharm Bull (Tokyo); 2016; 64(7):1004-8. PubMed ID: 27373663
[TBL] [Abstract][Full Text] [Related]
15. Probing Difference in Binding Modes of Inhibitors to MDMX by Molecular Dynamics Simulations and Different Free Energy Methods.
Shi S; Zhang S; Zhang Q
PLoS One; 2015; 10(10):e0141409. PubMed ID: 26513747
[TBL] [Abstract][Full Text] [Related]
16. Targeting the conformational transitions of MDM2 and MDMX: insights into dissimilarities and similarities of p53 recognition.
Macchiarulo A; Giacchè N; Carotti A; Baroni M; Cruciani G; Pellicciari R
J Chem Inf Model; 2008 Oct; 48(10):1999-2009. PubMed ID: 18826207
[TBL] [Abstract][Full Text] [Related]
17. Targeting the conformational transitions of MDM2 and MDMX: insights into key residues affecting p53 recognition.
Carotti A; Macchiarulo A; Giacchè N; Pellicciari R
Proteins; 2009 Nov; 77(3):524-35. PubMed ID: 19507240
[TBL] [Abstract][Full Text] [Related]
18. Dual function of MDM2 and MDMX toward the tumor suppressors p53 and RB.
Hernández-Monge J; Rousset-Roman AB; Medina-Medina I; Olivares-Illana V
Genes Cancer; 2016 Sep; 7(9-10):278-287. PubMed ID: 28050229
[TBL] [Abstract][Full Text] [Related]
19. Design and development of high affinity dual anticancer peptide-inhibitors against p53-MDM2/X interaction.
Rasafar N; Barzegar A; Mehdizadeh Aghdam E
Life Sci; 2020 Mar; 245():117358. PubMed ID: 32001262
[TBL] [Abstract][Full Text] [Related]
20. Efficient p53 activation and apoptosis by simultaneous disruption of binding to MDM2 and MDMX.
Hu B; Gilkes DM; Chen J
Cancer Res; 2007 Sep; 67(18):8810-7. PubMed ID: 17875722
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]